← Leaderboards
Fengtian Xue
University Of Maryland Baltimore
$2,809,086
Attributed
$5,212,608
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,212,608 · 4
By mechanism
R01$4,382,170 · 2
R21$830,438 · 2
Top collaborators
- Yan Shu3 shared
- Angela None Wilks2 shared
- Hongbing Wang1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Angela None Wilks$10,746,070
- Yan Shu$4,220,804
- Abraham Schneider$2,695,113
- Alecia Tennessee Dent$59,318
- Harry L. Mobley$24,735,775
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroSmall MoleculeIn VivoDesignCellsAnalogNovel Therapeutic InterventionLead OptimizationToxic EffectSignal TransductionAnimal ModelLiverMouse ModelPharmacologicHepatocyteStructure-Activity RelationshipGeneticPersonsDrug KineticsMedicalDrug DevelopmentBindingIn Vivo EvaluationComputer Assisted
Grant awards (8)
Impact of CAR and Nrf2 dual activation on cyclophosphamide bioactivation and doxorubicin detoxification$2,840,768
R01 · FY2025 · CA
Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis$485,056
R01 · FY2025 · DK
Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis$517,394
R01 · FY2024 · DK
ALDH2 inhibitors for the treatment of AUD$183,469
R21 · FY2024 · AA · contact PI
Axin Stabilization by Novel Small Molecules to Treat Non-alcoholic Steatohepatitis$538,952
R01 · FY2023 · DK
ALDH2 inhibitors for the treatment of AUD$222,094
R21 · FY2023 · AA · contact PI
Pseudomonas aeruginosa heme sensing inhibitors targeting HasAp$193,125
R21 · FY2022 · AI · contact PI
Pseudomonas aeruginosa heme sensing inhibitors targeting HasAp$231,750
R21 · FY2021 · AI · contact PI